Xtl Biopharmaceuticals (XTLB) Capital Expenditures (2011 - 2015)
Xtl Biopharmaceuticals (XTLB) posted quarterly Capital Expenditures of $4000.0 for Q4 2015, up 100.0% year-on-year from $2000.0 in Q4 2014, and up 300.0% on a QoQ basis from -$2000.0 in Q2 2015.
Xtl Biopharmaceuticals (XTLB) Capital Expenditures (2011 - 2015) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Capital Expenditures for 5 consecutive years, with $4000.0 the latest figure, recorded in Q4 2015.
- Quarterly Capital Expenditures rose 100.0% year-over-year to $4000.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $4000.0 (up 150.0% YoY) and the FY2024 annual result came in at -$54000.0, changed N/A from the prior year.
- Capital Expenditures grew to $4000.0 in Q4 2015 per XTLB's latest filing, from -$2000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for XTLB reached as high as $4000.0 in Q4 2015 and fell as low as -$74000.0 in Q4 2013.
- A 5-year average of -$7714.3 and a median of -$2000.0 in 2011 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2013 — Capital Expenditures slumped 1750.0% — and 2014, when it surged 102.7%.
- Year by year, Capital Expenditures stood at -$1000.0 in 2011, then tumbled by 300.0% to -$4000.0 in 2012, then sank by 1750.0% to -$74000.0 in 2013, then soared by 102.7% to $2000.0 in 2014, then surged by 100.0% to $4000.0 in 2015.
- According to Business Quant data, Capital Expenditures over the past three periods registered $4000.0, -$2000.0, and $2000.0 for Q4 2015, Q2 2015, and Q4 2014 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.41 Bn | 466.62 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 122.15 Bn | 114.90 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.94 Bn | 61.18 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 4,000.00 |
| Dec 31, 2015 | 4,000.00 |
| Jun 30, 2015 | -2,000.00 |
| Jun 30, 2015 | -2,000.00 |
| Dec 31, 2014 | 2,000.00 |
| Dec 31, 2014 | 2,000.00 |
| Jun 30, 2014 | -4,000.00 |
| Jun 30, 2014 | -4,000.00 |
| Mar 31, 2014 | -6,000.00 |
| Mar 31, 2014 | -6,000.00 |
| Dec 31, 2013 | -74,000.00 |
| Dec 31, 2013 | -74,000.00 |
| Jun 30, 2013 | -2,000.00 |
| Jun 30, 2013 | -2,000.00 |
| Mar 31, 2013 | -8,000.00 |
| Mar 31, 2013 | -8,000.00 |
| Dec 31, 2012 | -4,000.00 |
| Dec 31, 2012 | -4,000.00 |
| Sep 30, 2012 | -1,000.00 |
| Sep 30, 2012 | -1,000.00 |